GC Green Cross Wellbeing and Alteogen Biologics Sign Joint Sales Agreement for "Tergase" in Korea

Full-scale Entry into the Pain Management Market

GC Green Cross Wellbeing announced on April 16 that it has signed a domestic joint sales agreement with Alteogen Biologics for the human-derived recombinant hyaluronidase "Tergase," and will begin targeting the domestic market.

At the 'Tergajeju' co-sale agreement signing ceremony held at the Seoul Forest GC Green Cross Wellbeing headquarters, Sanghyun Kim, CEO of GC Green Cross Wellbeing (left), and Heejung Ji, CEO of Alteogen Bio (right), are taking a commemorative photo. GC Green Cross Wellbeing

The two companies held a joint sales contract signing ceremony at the Seoul Forest GC Green Cross Wellbeing headquarters on April 15, agreeing to cooperate on establishing "Tergase" in the market and expanding its market share. They plan to actively target the market through joint marketing and sales activities going forward.

"Tergase" is a finished pharmaceutical product containing human-derived recombinant hyaluronidase (ALT-B4), developed based on Alteogen's Hybrozyme™ technology. Unlike conventional animal-derived hyaluronidase products from sources such as cows or pigs, this product uses a gene recombination method to achieve higher purity and has significantly reduced immune-related side effects, thereby ensuring safety. The enzyme breaks down hyaluronic acid within tissues, facilitating the diffusion and absorption of drugs, and can be utilized in a variety of clinical settings such as postoperative pain management, local anesthesia diffusion, and improvement of filler-related side effects.

Alteogen Biologics will promote the market entry of "Tergase" and increase prescriptions in major medical departments by leveraging GC Green Cross Wellbeing's sales network, while GC Green Cross Wellbeing plans to strengthen sales through synergy with its existing pain management products. Both companies will focus on building a prescription base and accelerating market expansion by leveraging product competitiveness and sales capabilities.

Kim Sanghyun, CEO of GC Green Cross Wellbeing, stated, "Through this joint sales initiative, we will actively support the accelerated market entry of 'Tergase.' We aim to enhance product accessibility and increase its utility in various clinical settings."

Meanwhile, GC Green Cross Wellbeing intends to use this joint sales agreement as an opportunity to strengthen its portfolio of specialty pharmaceuticals in the pain management field and enhance its competitiveness in the non-reimbursed injectable drug business through synergies with existing operations.

This content was produced with the assistance of AI translation services.